trending Market Intelligence /marketintelligence/en/news-insights/trending/cahduJbCre9OdkOh5qJozQ2 content esgSubNav
In This List

Aerie Pharmaceuticals' Rhopressa gets US FDA approval to lower eye pressure

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Aerie Pharmaceuticals' Rhopressa gets US FDA approval to lower eye pressure

The U.S. Food and Drug Administration approved Aerie Pharmaceuticals Inc.'s Rhopressa 0.02% for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

The approval was made two months ahead of the scheduled approval date of Feb. 28, 2018.

Previously, an advisory panel for the FDA voted 9-1 in favor of Rhopressa, concluding that its benefits outweigh its risks.